India: Mergers, Acquisitions And Joint Venture: Trends In Bio-Similar Industries

Last Updated: 18 July 2017
Article by Vijaylaxmi Rathore

Most Read Contributor in India, December 2018

Mergers, acquisitions and joint ventures (M&As) amongst businesses are well known trends and often considered critical for the growth of a company. Additionally, M&As help to strengthen and explore market opportunities, functional and financial synergy along with ability to generate additional revenues. M&As further encourage cross-cultural growth, transfer of technical knowhow and administrative maturity and/or adaptation.

However, M&As do not always result in a success, especially amongst companies with different objectives and scope of businesses. At times companies tend to become overtly adamant leading to operative challenges while also facing difficulties in adapting to the cultural diversity in dissimilar markets. Nevertheless, in today's time, it is imperative to have M&As with the key players in an industry so as to grow and eventually become market leaders.

A "merger" is a combination of two or more entities at various degree into forming one entity. The result of merger is not only accumulation of assets and liabilities of the entities but also to form one business with the uniform objectives, finances, access to technologies and shared markets. On the other hand, an "acquisition" is a takeover by an acquirer entity by virtue of controlling the share capital, assets and/or liabilities of the target or acquired entity. Lastly, "joint ventures" are coming together of two or more businesses for a purpose such as entering into a new business and/or new expertise, or for investments, which may or may not be for a limited duration.

The different forms of mergers are explained under Competition Act, 2002:

  • Horizontal Merger- The merging entities are from the similar industries. This merger supports merged entity towards monopoly by removing competitor. As far as the competition concern this merger is performed under competition commission.
  • Vertical Merger- The merging entities are at different stage even though from similar industries. This merger supports merged entity towards greater independence and self sufficiency.
  • Congeneric Merger- The merging entities with different customer-relationship even though from interrelated industries. This merger supports merged entity's market growth by using aggregated customer relationship.
  • Conglomerate Merger- The merging entities are from the different industries. This merger results in support for the merged entity by financial resources and increased market value.
  • Cash Merger- The shareholder of one entity receives cash instead of shares and exit from the merged entity.
  • Triangular Merger- This is a tri-partite arrangement as a target merges with a subsidiary of acquirer and vice versa, also called triangular mergers.

Mergers, Acquisitions and Joint ventures in BIOSIMILAR Industries:

A "biosimilar" is a biological drug that has similar pharmaceutical standards, safety and efficacy profile vis-à-vis an approved reference biological molecule. However, unlike generics, biosimilars do not have structural similarities or they do not form replica of the original molecule. A biopharmaceutical entity dedicated to developing, manufacturing and marketing of the biosimilars as part of its therapeutic portfolio is called a Biosimilar Entity.

In contemporary times, the increased demand of biosimilars is not only beneficial to the Biosimilar entities, but also offers more viable options to the consumers or patients requiring treatment especially for diseases like cancer, cardiovascular disorders, arthritis, etc. Mergers and acquisitions (M&As) in Biosimilar industries are primary to strengthen the service, brand, and patient accessibility for a certain drug. Moreover, Biosimilars M&As also help to overcome challenges such as seeking investments, research and development, process manufacturing, marketing and/or distribution of biosimilars. Here are some of the prominent M&As from biosimilar industries-

1. The Pfizer's acquisition of Hospira:

The acquisition of Hospira by Pfizer for $17 billion is one of the biggest horizontal mergers in recent years and has been approved conditionally by European Commission (EC) Merger Regulation after investigating the competition concerns and commitments offered by the merging companies6. Both Pfizer and Hospira are US based industries, and global provider of injectable, biosimilars and human pharmaceuticals respectively. Therefore, the said acquisition helps Pfizer to expand its existing generic injectable drugs range as well as access over the infusion technology and new  category of biosimilars are collectively expected to generate revenues of $800 million annually by 20187.

Hospira, Inc. is now a subsidiary of Pfizer Inc. and the global market for biosimilars is estimated to be approximately $20 billion in 2020. However, Hospira's biosimilars and generics range already helped to raise 11% revenues of Pfizer as reported on its second quarter result after acquisitions8. Later Pfizer started to take a bid from Hospira's few units and sites which seem underutilized as a part of cost cutting and improvisation in company performance. In later 2016, Pfizer sold out Hospira's Infusion System (HIS) to ICU medical and also planning to close Hospira's plant at Colorado9 and few sites at USA by 201910.

2. The ICU Medical's acquisition of Hospira from Pfizer:

A deal between Pfizer and ICU Medical Inc. comes out as a cash and stock deal, as ICU acquired Hospira's Infusion System (HIS) having IV pumps, solutions, and devices from Pfizer, which compliments ICU existing Intravenous product portfolio. Consequently, ICU is expected to become a bigger player of infusions by this deal with Hospira enhanced global marketing platform. The deal is settled for $1 Billion by exchange of cash of $600 million, $400 million newly issued shares of ICU Medical apart from this Pfizer will nominate one member on ICU Medical's board as long as it hold 10% of its equity11.

However, in January 2017 the definitive agreement between ICU and Pfizer for Hospira Infusion System (HIS) has been revised, as the latest performance report of HIS deviates as expected. Based on the modified agreement the deal is settled for $900 million ($400 million in equity + $275 millions cash + $75 million seller note). Pfizer may be receiving additional $225 based on the HIS performance target till December 2019.

As per Mr. Vivek Jain, Chief Executive Officer, ICU Medical "The combination of these two businesses is the natural evolution of a productive relationship that began more than 20 years ago when Hospira began integrating ICU Medical needle free technology into their infusion offering globally" 12.

3. Gedeon Richter acquisitions of Finox holding:

The Hungarian drugmaker Gedeon Richter acquire of Finox holding, a Swiss Biotech firm for $ 190 million. Finox holding, a leading producer of wide range female reproductive health products has handed over the global right of Bemfola development and marketing to Richter by this transaction. Bemfola is a recombinant-human Follicle Stimulating Hormone (r-hFSH) biosimilar of Gonal-f, which stimulates egg development in ovaries and suggested during in-vitro fertilization. The global right of Bemfola includes the exclusive marketing authorization in EU, presently counting 20 countries where drug is being sold already, excluding marketing authorization in USA13.

This acquisition helps Richter not only to strengthen and expand its existing women healthcare portfolio by using Finox scientific and managerial expertise. But, also to further expand its dedication towards biosimilar development and commercialization. The leading approach and expertise of Richter toward development and marketing of female fertility product worldwide will definitely get boost by Finox existing portfolio.

The leading Biopharmaceuticals are acquiring more firms, like GE Healthcare acquisitions of Xcellerex Inc., Amgen acquires Onyx Pharmaceuticals etc., with aim to monopolize and mark their presence as leading player in health care industry.

4. The newer player: Aurobindo acquired four biosimilars from TL Biopharmaceutical

Aurobindo Pharma Ltd., an Indian generic pharmaceutical industry is expanding its diverse portfolio specifically the biosimilars manufacturing by acquiring four licensed biosimilars from a swiss firm TL Biopharmaceutical AG in undisclosed amount. Aurobindo Pharma will get development, commercialization and marketing rights of these Biosimilars, three out of four acquired products are anticancer monoclonal antibodies, and one of lead molecule bevacizumab from this transaction is expected to conduct a clinical trial this year. Aurobindo will acquire eight more biosimilars in future to strengthen its biosimilar

portfolio. The company has been building a biosimilar manufacturing facility in Hyderabad. The transaction is a strategic investment for future growth and will position Aurobindo as a strong player in the rapidly evolving biosimilars landscape, according to the company14.

Likewise Eagle Pharma acquires Arsia Therapeutics, Fresenius Kabi acquisitions to Merck KGaA and many more new players are making their entry to biosimilar portfolio by M&A.


The primary goal of an M&A is to strengthen and expand the functional and financial synergies of the merged entities while also enabling exploration of new portfolios or business sectors for the said entities. Further, at times M&A also results in market leadership by merger of entities of same/similar industries. In biosimilar industry, we see a considerable increase in coming together of entities which has led to faster growth of the industry and increased demand of biosimilars.

Biopharmaceutical firms often differ in functional, financial, customer related services and other aspects. Therefore, the conventional M&A gets modified at various levels and with mixed ratios based on the interest areas and objectives of participating entities, for e.g., The ICU Medical's acquisition of Hospira from Pfizer is a mixed M&A.

Firms new to biosimilars such as Aurobindo, Eagle Pharma etc., are showing interest towards building and acquiring biosimilar portfolio as a part of greater therapeutic coverage and to charter the global markets. On the other hand, the leading producers of biosimilars like- Sandoz, Teva Pharmaceutical, Amgen, Mylan, AbbVie etc., are stepping slowly toward monopolization of the market by M&A with promising biosimilar entities.

The trend of increased M&As in the biosimilar industry would lead to advanced research & development in the sector and will infuse competition amongst pharmaceutical firms which will hopefully result in efficacious and safer biosimilar innovations for diagnosis and treatment of diseases.











The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions